RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $130 Price Target

Benzinga · 1d ago
RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $130 price target.